Tissue Non-Specific Alkaline Phosphatase and Vascular Calcification: A Potential Therapeutic Target

Author(s): Daniel Azpiazu, Sergio Gonzalo, Ricardo Villa-Bellosta*.

Journal Name: Current Cardiology Reviews

Volume 15 , Issue 2 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Vascular calcification is a pathologic phenomenon consisting of calcium phosphate crystal deposition in the vascular walls. Vascular calcification has been found to be a risk factor for cardiovascular diseases, due to its correlation with cardiovascular events and mortality, and it has been associated with aging, diabetes, and chronic kidney disease.

Studies of vascular calcification have focused on phosphate homeostasis, primarily on the important role of hyperphosphatemia. Moreover, vascular calcification has been associated with loss of plasma pyrophosphate, one of the main inhibitors of calcification, thus indicating the importance of the phosphate/pyrophosphate ratio.

Extracellular pyrophosphate can be synthesized from extracellular ATP by ecto-nucleotide pyrophosphatase/ phosphodiesterase, whereas pyrophosphate is hydrolyzed to phosphate by tissuenonspecific alkaline phosphatase, contributing to the formation of hydroxyapatite crystals.

Over the last decade, vascular calcification has been the subject of numerous reviews and studies, which have revealed new agents and activities that may aid in explaining the complex physiology of this condition. This review summarizes current knowledge about alkaline phosphatase and its role in the process of vascular calcification as a key regulator of the phosphate/pyrophosphate ratio.

Keywords: Vascular calcification, TNAP, alkaline phosphatase, pyrophosphate, hemodialysis, CKD, aging.

[1]
Villa-Bellosta R, Egido J. Phosphate, pyrophosphate, and vascular calcification: A question of balance. Eur Heart J 2017; 38: 1801-4.
[2]
Blumenthal HT, Lansing AI, Wheeler PA. Calcification of the media of the human aorta and its relation to intimal arteriosclerosis, ageing and disease. Am J Pathol 1944; 20: 665-87.
[3]
Nicoll R, Henein MY. The predictive value of arterial and valvular calcification for mortality and cardiovascular events. Int J Cardiol Heart Vessels 2014; 3: 1-5.
[4]
Cecelja M, Chowienczyk P. Role of arterial stiffness in cardiovascular disease JRSM Cardiovasc Dis 2012; 1(4) pii: cvd.2012.012016
[5]
Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011; 109: 697-711.
[6]
Villa-Bellosta R. Synthesis of extracellular pyrophosphate increases in vascular smooth muscle cells during phosphate-induced calcification. Arterioscler Thromb Vasc Biol 2018; 38: 2137-47.
[7]
Farzaneh-Far A, Proudfoot D, Shanahan C, Weissberg PL. Vascular and valvar calcification: Recent advances. Heart Br Card Soc 2001; 85: 13-7.
[8]
Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: Prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv 2014; 83: E212-20.
[9]
Desai MY, Cremer PC, Schoenhagen P. Thoracic aortic calcification: Diagnostic, prognostic, and management considerations. JACC Cardiovasc Imaging 2018; 11: 1012-26.
[10]
Andrews J, Psaltis PJ, Bartolo BAD, Nicholls SJ, Puri R. Coronary arterial calcification: A review of mechanisms, promoters and imaging. Trends Cardiovasc Med 2018; 28: 491-501.
[11]
Shekar C, Budoff M. Calcification of the heart: Mechanisms and therapeutic avenues. Expert Rev Cardiovasc Ther 2018; 16: 527-36.
[12]
Myasoedova VA, Ravani AL, Frigerio B, et al. Novel pharmacological targets for calcific aortic valve disease: Prevention and treatments. Pharmacol Res 2018; 136: 74-82.
[13]
Proudfoot D, Shanahan CM. Biology of calcification in vascular cells: Intima versus media. Herz 2001; 26: 245-51.
[14]
Panh L, Lairez O, Ruidavets JB, Galinier M, Carrié D, Ferrières J. Coronary artery calcification: From crystal to plaque rupture. Arch Cardiovasc Dis 2017; 110: 550-61.
[15]
Ho CY, Shanahan CM. Medial arterial calcification: An overlooked player in peripheral arterial disease. Arterioscler Thromb Vasc Biol 2016; 36: 1475-82.
[16]
Iyemere VP, Proudfoot D, Weissberg PL, Shanahan CM. Vascular smooth muscle cell phenotypic plasticity and the regulation of vascular calcification. J Intern Med 2006; 260: 192-210.
[17]
Schibler D, Russell RG, Fleisch H. Inhibition by pyrophosphate and polyphosphate of aortic calcification induced by vitamin D3 in rats. Clin Sci 1968; 35: 363-72.
[18]
Lee SY, Müller CE. Nucleotide pyrophosphatase/phosphodieste-rase 1 (NPP1) and its inhibitors. MedChemComm 2017; 8: 823-40.
[19]
Perrakis A, Moolenaar WH. Autotaxin: Structure-function and signaling. J Lipid Res 2014; 55: 1010-8.
[20]
Bobryshev YV, Orekhov AN, Sobenin I, Chistiakov DA. Role of bone-type tissue-nonspecific alkaline phosphatase and PHOSPO1 in vascular calcification. Curr Pharm Des 2014; 20: 5821-8.
[21]
Villa-Bellosta R, Wang X, Millán JL, Dubyak GR, O’Neill WC. Extracellular pyrophosphate metabolism and calcification in vascular smooth muscle. Am J Physiol Heart Circ Physiol 2011; 301: H61-8.
[22]
Rutsch F, Vaingankar S, Johnson K, et al. PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am J Pathol 2001; 158: 543-54.
[23]
Lomashvili KA, Garg P, Narisawa S, Millan JL, O’Neill WC. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: Potential mechanism for uremic vascular calcification. Kidney Int 2008; 73: 1024-30.
[24]
Millán JL. Alkaline Phosphatases : Structure, substrate specificity and functional relatedness to other members of a large superfamily of enzymes. Purinergic Signal 2006; 2: 335-41.
[25]
Sharma U, Pal D, Prasad R. Alkaline phosphatase: An overview. Indian J Clin Biochem IJCB 2014; 29: 269-78.
[26]
Robison R. The possible significance of hexosephosphoric esters in ossification. Biochem J 1923; 17: 286-93.
[27]
Manes T, Glade K, Ziomek CA, Millán JL. Genomic structure and comparison of mouse tissue-specific alkaline phosphatase genes. Genomics 1990; 8: 541-54.
[28]
Harrison G, Shapiro IM, Golub EE. The phosphatidylinositol-glycolipid anchor on alkaline phosphatase facilitates mineralization initiation in vitro. J Bone Miner Res 1995; 10: 568-73.
[29]
Yamasaki K, Hagiwara H. Excess iron inhibits osteoblast metabolism. Toxicol Lett 2009; 191: 211-5.
[30]
Villa-Bellosta R. Impact of magnesium:calcium ratio on calcification of the aortic wall. PLoS One 2017; 12: e0178872.
[31]
Buchet R, Millán JL, Magne D. Multisystemic functions of alkaline phosphatases. Methods Mol Biol Clifton NJ 2013; 1053: 27-51.
[32]
Holtz KM, Kantrowitz ER. The mechanism of the alkaline phosphatase reaction: Insights from NMR, crystallography and site-specific mutagenesis. FEBS Lett 1999; 462: 7-11.
[33]
Conti F, Ciullini L, Pugliese G. Hypophosphatasia: Clinical manifestation and burden of disease in adult patients. Clin Cases Miner Bone Metab 2017; 14: 230-4.
[34]
Simon S, Resch H, Klaushofer K, Roschger P, Zwerina J, Kocijan R. Hypophosphatasia: From diagnosis to treatment. Curr Rheumatol Rep 2018; 20: 69.
[35]
Millán JL, Whyte MP. Alkaline phosphatase and hypophosphatasia. Calcif Tissue Int 2016; 98: 398-416.
[36]
Whyte MP, Greenberg CR, Salman NJ, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 2012; 366: 904-13.
[37]
Bowden SA, Foster BL. Profile of asfotase alfa in the treatment of hypophosphatasia: Design, development, and place in therapy. Drug Des Devel Ther 2018; 12: 3147-61.
[38]
Rathan S, Yoganathan AP, O’Neill CW. The role of inorganic pyrophosphate in aortic valve calcification. J Heart Valve Dis 2014; 23: 387-94.
[39]
Villa-Bellosta R, O’Neill WC. Pyrophosphate deficiency in vascular calcification. Kidney Int 2018; 93: 1293-7.
[40]
Lomashvili KA, Narisawa S, Millán JL, O’Neill WC. Vascular calcification is dependent on plasma levels of pyrophosphate. Kidney Int 2014; 85: 1351-6.
[41]
Lomashvili KA, Khawandi W, O’Neill WC. Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol 2005; 16: 2495-500.
[42]
Villa-Bellosta R, González-Parra E, Egido J. Alkalosis and dialytic clearance of phosphate increases phosphatase activity: A hidden consequence of hemodialysis. PLoS One 2016; 11: e0159858.
[43]
Villa-Bellosta R, Rivera-Torres J, Osorio FG, et al. Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment. Circulation 2013; 127: 2442-51.
[44]
Riser BL, Barreto FC, Rezg R, et al. Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model of uraemia. Nephrol Dial Transplant 2011; 26: 3349-57.
[45]
O’Neill WC, Lomashvili KA, Malluche HH, Faugere MC, Riser BL. Treatment with pyrophosphate inhibits uremic vascular calcification. Kidney Int 2011; 79: 512-7.
[46]
Lomashvili KA, Cobbs S, Hennigar RA, Hardcastle KI, O’Neill WC. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J Am Soc Nephrol 2004; 15: 1392-401.
[47]
Azpiazu D, González-Parra E, Egido J, Villa-Bellosta R. Hydrolysis of Extracellular Pyrophosphate increases in post-hemodialysis plasma. Sci Rep 2018; 8: 11089.
[48]
Narisawa S, Yadav MC, Millán JL. In vivo overexpression of tissue-nonspecific alkaline phosphatase increases skeletal mineralization and affects the phosphorylation status of osteopontin. J Bone Miner Res 2013; 28: 1587-98.
[49]
Narisawa S, Harmey D, Yadav MC, O’Neill WC, Hoylaerts MF, Millán JL. Novel inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification. J Bone Miner Res 2007; 22: 1700-10.
[50]
Kiffer-Moreira T, Yadav MC, Zhu D, et al. Pharmacological inhibition of PHOSPHO1 suppresses vascular smooth muscle cell calcification. J Bone Miner Res 2013; 28: 81-91.
[51]
Yadav MC, Simão AMS, Narisawa S, et al. Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function: A unified model of the mechanisms of initiation of skeletal calcification. J Bone Miner Res 2011; 26: 286-97.
[52]
Fakhry M, Roszkowska M, Briolay A, et al. TNAP stimulates vascular smooth muscle cell trans-differentiation into chondrocytes through calcium deposition and BMP-2 activation: Possible implication in atherosclerotic plaque stability. Biochim Biophys Acta 2017; 1863: 643-53.
[53]
Haarhaus M, Brandenburg V, Kalantar-Zadeh K, Stenvinkel P, Magnusson P. Alkaline phosphatase: A novel treatment target for cardiovascular disease in CKD. Nat Rev Nephrol 2017; 13: 429-42.
[54]
al-Rashida M, Iqbal J. Therapeutic potentials of ecto-nucleoside triphosphate diphosphohydrolase, ecto-nucleotide pyrophosphatase/phosphodiesterase, ecto-5′-nucleotidase, and alkaline phosphatase inhibitors. Med Res Rev 2014; 34(4): 703-43.
[55]
Hsu HH, Anderson HC. The isolation and partial sequencing of human bone alkaline phosphatase gene. Int J Biochem 1989; 21(8): 847-51.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 2
Year: 2019
Page: [91 - 95]
Pages: 5
DOI: 10.2174/1573403X14666181031141226
Price: $58

Article Metrics

PDF: 40
HTML: 4
EPUB: 1
PRC: 1